Repurposing drugs in oncology (ReDO)—cimetidine as an anti-cancer agent

DSpace/Manakin Repository

Repurposing drugs in oncology (ReDO)—cimetidine as an anti-cancer agent

Citable link to this page


Title: Repurposing drugs in oncology (ReDO)—cimetidine as an anti-cancer agent
Author: Pantziarka, Pan; Bouche, Gauthier; Meheus, Lydie; Sukhatme, Vidula; Sukhatme, Vikas P

Note: Order does not necessarily reflect citation order of authors.

Citation: Pantziarka, Pan, Gauthier Bouche, Lydie Meheus, Vidula Sukhatme, and Vikas P Sukhatme. 2014. “Repurposing drugs in oncology (ReDO)—cimetidine as an anti-cancer agent.” ecancermedicalscience 8 (1): 485. doi:10.3332/ecancer.2014.485.
Full Text & Related Files:
Abstract: Cimetidine, the first H2 receptor antagonist in widespread clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical and clinical studies for a number of different cancer types. These data are summarised and discussed in relation to a number of distinct mechanisms of action. Based on the evidence presented, it is proposed that cimetidine would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of cimetidine as an anti-cancer therapeutic is warranted. Furthermore, there is compelling evidence that cimetidine administration during the peri-operative period may provide a survival benefit in some cancers. A number of possible combinations with other drugs are discussed in the supplementary material accompanying this paper.
Published Version: doi:10.3332/ecancer.2014.485
Other Sources:
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at
Citable link to this page:
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)


Search DASH

Advanced Search